Brief: PhaseBio Doses First Patients In Canada As Part Of REVERSE-IT Global Phase 3 Trial Of Bentracimab

PhaseBio Pharmaceuticals

06/10/2020 13:03

Oct 6 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO DOSES FIRST PATIENTS IN CANADA AS PART OF THE
REVERSE-IT GLOBAL PHASE 3 TRIAL OF BENTRACIMAB FOR REVERSAL OF
THE ANTIPLATELET EFFECTS OF TICAGRELOR
    * PHASEBIO PHARM - BENTRACIMAB HAS DEMONSTRATED IMMEDIATE,
SUSTAINED REVERSAL OF ANTIPLATELET EFFECTS OF TICAGRELOR IN BOTH
PHASE 1, PHASE 2 TRIALS
    * PHASEBIO PHARMACEUTICALS INC - ONGOING GLOBAL PHASE 3
TRIAL OF
BENTRACIMAB HAS BEEN NAMED REVERSE-IT

Source text for Eikon:  ID:nBwbhbJ35a 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))